Development of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide and semaglutide, were initially developed for the treatment of type 2 diabetes but were found to be effective not only in reducing blood glucose levels but body weight as well [18,19,20]
& Underhill, D
We may earn commissions from affiliate links at no extra cost to you
is supported by an Australian National Health and Medical Research Council Senior Principal Research Fellowship (GNT1059660) and has received grants from the US NIH, the Australian Cooperative Research Centre, the Simons Autism Foundation, the Cancer Council of Victoria, the Stanley Medical Research Foundation, the Medical Benefits Foundation, Beyond Blue, Rotary Health and the Geelong Medical Research Foundation
Wegovy What Is the Difference
It functions as a standard support channel for questions that arent urgent